



# Kinase assay to aid in development of therapeutics for acute myeloid leukemia

**Peptide substrates to sensitively and specifically measure the real-time activity of FLT3, a kinase linked to acute myeloid leukemia.**

**IP Status:** Issued US Patent; Patent No. 10,590,168

## Applications

- Clinical diagnostic to determine AML behavior and optimal treatment strategy
- Oncology research on mechanism of resistance development in cancers (specifically AML)
- Chemotherapeutic drug identification and development
- Basic kinase research

## Key Benefits & Differentiators

- **Highly selective and specific:** Perform 200% better compared to the currently available FLT3 substrate, capable of providing real-time activity measurements in live cells.
- **Multiple readouts amenable to high throughput assays:** Phosphorylation of the substrate can be measured using ELISA, mass spectrometry, or through incorporation of terbium binding segments eliciting a fluorescent readout.
- **Use with wild-type, unmodified kinases:** Does not require the modification or tagging of kinases prior to experimentation.

## FLT3's heavy role in AML

Fms-like tyrosine kinase 3 (FLT3) kinase is one of the most frequently mutated genes in acute myeloid leukemia (AML). Early studies have shown that mutations in FLT3 are correlated with poor long-term prognosis with increased risk for relapse. To assess FLT3 activity, Laurie Parker's lab at the University of Minnesota designed substrates phosphorylated by FLT3 in a manner that is highly efficient and specific. Coupled with fluorescent and/or mass spectrometric readouts, these peptides are valuable tools in both drug discovery and diagnostics for FLT3-linked AML.

## Measuring FLT3 activity to develop diagnostics and discover therapeutics

The developed FLT3 artificial substrates (FAS-A) is compatible with living cells and facilitates rapid detection of kinase activity in real time. When compared to alternatives, FAS-A is phosphorylated 200% more effectively than the only other FLT3 substrate reported in the literature (FLT3tide). Due to its high selectivity, FAS-A can be used in complex lysates or mixtures and with negligible off-target effects and can be multiplexed with other assays. Finally, the phosphorylation of the substrate can be measured using ELISA, mass spectrometry, or through incorporation of terbium binding segments, facilitating a fluorescent readout. This flexibility facilitates the use of the substrate in a wide variety of applications including high-throughput and drug discovery methods.

## Phase of Development

## Technology ID

20160394

## Category

Life Sciences/Biomarkers  
Life Sciences/Diagnostics & Imaging  
Life Sciences/Human Health  
Life Sciences/Pharmaceuticals  
Life Sciences/Research Tools  
Gap Funding/Life Sciences  
Gap Funding/Medical Tech

## Learn more



Multiple designed substrates of wildtype and mutant forms of FLT3 assessed in vitro.

### Researchers

Laurie Parker, PhD

Associate Professor, Biochemistry, Molecular Biology and Biophysics

[External Link](http://cbs.umn.edu) (cbs.umn.edu)

### Publications

[High-throughput Identification of FLT3 Wild-type and Mutant Kinase Substrate Preferences and Application to Design of Sensitive In Vitro Kinase Assay Substrates](#)  
*Molecular and Cellular Proteomics*, 2019

### Seeking Industry Partners

This technology is now available for:

- License
- Sponsored research
- Collaborative development

Please contact us to share your business' needs and learn more.

MN-IP Try and Buy
<b>Try</b> <ul style="list-style-type: none"><li>• Trial period is up to 12 months</li><li>• Trial fee is \$6,000 for a 12 month period</li><li>• No US patent fees during Try period</li></ul>
<b>Buy</b> <ul style="list-style-type: none"><li>• \$25,000 conversion fee (TRY to BUY)</li><li>• \$5000 annual minimum credited against royalties thereafter</li><li>• Royalty rate of 3% (2% for MN company)</li><li>• Royalty free for first \$1M in sales</li></ul>